Stock Ratings / Industrials / NIKI / financials

UCAR (23) RETO (29) DFLI (34) XPON (50) ⌘ Pro Terminal →

Niki BioSolutions Inc. (NIKI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Is NIKI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Niki BioSolutions Inc. (NASDAQ: NIKI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.96 (+1.88% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 485 tracked Industrials issuers, NIKI ranks #404 in composite RQD confidence.

Q: How does NIKI compare to UCAR and RETO in the Industrials sector?

Within the Industrials sector (Industrial Machinery/Components), NIKI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.9%. By comparison, UCAR (U Power Limited (Class A)) holds a E grade (23/100 RQD, P/E N/A, ROIC -18.5%, cap $5.1M) and RETO (ReTo Eco-Solutions Inc. (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, NIKI leads on earnings multiple (N/A) while NIKI leads on capital efficiency (-5.9% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for NIKI?

Per NIKI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001734005), Niki BioSolutions Inc. generated $0 in revenue, -$1.4M in net income, and -$1.8M in free cash flow against $18.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is NIKI trading relative to its 50-day, 200-day, and 52-week technical levels?

NIKI last traded at $1.96 (+1.88% on volume of 5,575 shares), positioning the stock -57.67% below its 50-day simple moving average ($4.63) and -74.58% below its 200-day simple moving average ($7.71). Across its 52-week range of $1.70 to $17.20, NIKI sits at the 1.7% percentile with a 14-day RSI of 21.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.72 to $2.20).

Q: How profitable is Niki BioSolutions Inc. (NIKI)?

In FY 2025 (10-K), NIKI converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$1.96 +1.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.96

Niki BioSolutions Inc. (NIKI) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $5.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.96 (+0.15%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NIKI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY NIKI SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 21 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.00-49.3% Next Q

Q2 (-2Q)

Grade D$2.03-9.9% Next Q

Q3 (-1Q)

Grade D$1.83+7.1% Next Q

Current

Grade D-$1.96-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NIKI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NIKI currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Industrials with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.63) and Max Pain ($2.06) forces dealer call-delta covering toward $18.06.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NIKI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NIKI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NIKI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $431.4K

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	0%	-$1.4M	-$1.8M	-5.9%
FY 2024	$4.00B	52%	0%	-$4.3M	-$1.2M	-5.9%
FY 2023	$431.4K	52%	0%	-$2.8M	-$7.7M	-5.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NIKI)

✓Walkthrough of NIKI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NIKI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -77.60%▼ SUPPORT BREAKDOWN

2026-10-30O $1.81H $1.96L $1.70C $1.96VOL 9.7K

RES: $6.74SUP: $2.48SMA50: $4.63SMA200: $7.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NIKI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NIKI Butterfly Map → + Track NIKI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NIKI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NIKI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NIKI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NIKI)

Industrials Rank #404 of 485 ⚔️ UCAR vs NIKI Full Matrix →

1. Head-to-Head Industrials Peer Comparison (NIKI vs. UCAR, RETO, DFLI, XPON)

Industry: Industrial Machinery/Components (208 Tracked Issuers)

Across 485 tracked Industrials securities in the Roarable RQD universe, Niki BioSolutions Inc. (NIKI) ranks #404 by composite RQD confidence (37/100, grade D-) and #458 by equity capitalization ($5.7M). Within this direct 5-issuer industry benchmark cohort, NIKI leads on earnings valuation at N/A trailing P/E, while NIKI leads on capital efficiency and profitability with -5.9% ROIC and — gross margin. XPON currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with NIKI at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NIKI ACTIVE Niki BioSolutions Inc.	D-	37/100	—	—	-5.9%	+1.88%	$5.7M	Benchmark Subject
UCAR U Power Limited (Class A)	E	23/100	—	36.3%	-18.5%	-5.00%	$5.1M	/ucar-vs-niki →
RETO ReTo Eco-Solutions Inc. (Class A)	E	29/100	—	35.3%	-35.0%	-21.03%	$4.7M	/reto-vs-niki →
DFLI Dragonfly Energy Holdings Corp. (NV)	E	34/100	—	26.7%	-35.0%	+3.11%	$4.3M	/dfli-vs-niki →
XPON Expion Energy Inc.	D	50/100	—	13.9%	-35.0%	+5.20%	$4.1M	/xpon-vs-niki →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001734005

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Niki BioSolutions Inc. (NIKI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$1.4M, operating cash flow of -$1.8M, and free cash flow of -$1.8M (-54.4% YoY). On the balance sheet, NIKI closed FY2025 with $18.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$1.4M	-$1.8M	-$1.8M	$18.7M	—
FY2024 (FY)	2024-12-31	$0	-$4.3M	-$1.2M	-$1.2M	$16.1M	—
FY2023 (FY)	2023-12-31	$431.4K	-$2.8M	-$7.7M	-$7.7M	—	—

3. NIKI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NIKI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Niki BioSolutions Inc. (NASDAQ: NIKI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.96 (+1.88% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 485 tracked Industrials issuers, NIKI ranks #404 in composite RQD confidence.

How does NIKI compare to UCAR and RETO in the Industrials sector?

Within the Industrials sector (Industrial Machinery/Components), NIKI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.9%. By comparison, UCAR (U Power Limited (Class A)) holds a E grade (23/100 RQD, P/E N/A, ROIC -18.5%, cap $5.1M) and RETO (ReTo Eco-Solutions Inc. (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, NIKI leads on earnings multiple (N/A) while NIKI leads on capital efficiency (-5.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NIKI?

Per NIKI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001734005), Niki BioSolutions Inc. generated $0 in revenue, -$1.4M in net income, and -$1.8M in free cash flow against $18.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NIKI trading relative to its 50-day, 200-day, and 52-week technical levels?

NIKI last traded at $1.96 (+1.88% on volume of 5,575 shares), positioning the stock -57.67% below its 50-day simple moving average ($4.63) and -74.58% below its 200-day simple moving average ($7.71). Across its 52-week range of $1.70 to $17.20, NIKI sits at the 1.7% percentile with a 14-day RSI of 21.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.72 to $2.20).

NIKI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Niki BioSolutions Inc. (NIKI)?

In FY 2025 (10-K), NIKI converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: NIKI RQD Cockpit NIKI 12M Forecast NIKI Earnings & Move NIKI Dividends & DRIP NIKI Insiders & 13F NIKI Whale Options NIKI Profit Sankey NIKI News & Why